Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications
Open accessThe DOI matches its Crossref record; 130 of the 132 references it cites were found in a registry or an index.
Abstract
Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic, and viral infections. The severe acute respiratory syndrome (SARS)-CoV-2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with type 2 diabetes (T2D). Two coronavirus receptor proteins, angiotensin-converting enzyme 2 (ACE2) and dipeptidyl peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here, we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“however, just like for ACE inhibitors, there is currently insufficient scientific evidence to judge whether use of DPP4 inhibitors impacts adversely on type 2 diabetes patients with COVID-19 (28).”
From ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency (2020) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“The results of several large studies examining the cardiovascular safety of GLP-1R agonists did not reveal imbalances in rates of inflammatory disorders or severe infections (113) (114) (115) (116) .”
ResultSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“The results of several large studies examining the cardiovascular safety of GLP-1R agonists did not reveal imbalances in rates of inflammatory disorders or severe infections (113) (114) (115) (116) .”
ResultHamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676 · cited 9×
“1), and generates vasodilatory Ang (1-7), collectively modulating often opposing actions of Ang II and ACE through Ang and angiotensin (1-7) receptors.”
BackgroundInfluentialGrasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469 · cited 2×
“form ACE2(1-740), however the biological importance of sACE2 remains uncertain.”
BackgroundCase-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy
Onder, G., Rezza, G., & Brusaferro, S. (2020) · JAMA · doi:10.1001/jama.2020.4683 · Cited by 4,171
Comorbidity and its impact on 1590 patients with covid-19 in China: a nationwide analysis
Guan, W.-J., Liang, W.-H., Zhao, Y., Liang, H.-R., Chen, Z.-S., Li, Y.-M., Liu, X.-Q., Chen, R.-C., Tang, C.-L., Wang, T., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00547-2020 · Cited by 3,680
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 2×
“Consistent with these findings, results of large trials examining the safety of saxagliptin, alogliptin, sitagliptin, and linagliptin in humans with T2D at risk for cardiovascular or renal disease did not reveal clinically relevant safety concerns related to infections, immune or inflammatory disorders (96-100).”
BackgroundResult
Research works printed but not linked: 1
- Audit I. ICNARC Report on COVID-19 in Critical Care. In. April 10 2020 ed: London, UK: Intensive Care National Audit & Research Centre (ICNARC); 2020. https:// www.icnarc.org/About/Latest-News/2020/04/04/ Report-On-2249-Patients-Critically-Ill-With-Covid-19
Cited by
Items 101–200 of 433
Pinheiro, M. M., Fabbri, A., & Infante, M. (2021) · Immunotherapy · doi:10.2217/imt-2020-0349 · Cited by 46
Vitamin D deficiency in patients with diabetes and COVID- 19 infection
Singh, S., Jain, R., & Singh, S. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.06.071 · Cited by 45
COVID-19: the endocrine opportunity in a pandemic
Chatterjee, S., Ghosh, R., Biswas, P., Dubey, S., Guria, R. T., Sharma, C. B., & Kalra, S. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03216-2 · Cited by 44
Infante, M., Ricordi, C., Alejandro, R., Caprio, M., & Fabbri, A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1799785 · Cited by 44
Obesity and COVID ‐19: A jigsaw puzzle with still missing pieces
Michalakis, K. G., Panagiotou, G., Ilias, Ι., & Pazaitou‐Panayiotou, K. (2020) · Clinical Obesity · doi:10.1111/cob.12420 · Cited by 44
Factors Behind the Higher COVID-19 Risk in Diabetes: A Critical Review
Beshbishy, A. M., Oti, V. B., Hussein, D. E. E., Rehan, I. F., Adeyemı, O. S., Rivero-Pérez, N., Zaragoza-Bastida, A., Shah, M. A., Abouelezz, K., Hetta, H. F., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.591982 · Cited by 43
Brooks, D., Schulman‐Rosenbaum, R., Griff, M., Lester, J., & Wang, C. C. L. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.07.014 · Cited by 43
The burden of type 2 diabetes pre-and during the COVID-19 pandemic – a review
Sciberras, J., Camilleri, L. M., & Cuschieri, S. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00656-4 · Cited by 42
Type 2 Diabetes Mellitus and COVID-19: A Narrative Review
Rey‐Reñones, C., Martínez‐Torres, S., Martín‐Luján, F., Pericas, C., Redondo, A., Vilaplana-Carnerero, C., Domínguez, Á., & Grau, M. (2022) · Biomedicines · doi:10.3390/biomedicines10092089 · Cited by 41
Mani, V. R. K., Kalabin, A., Valdivieso, S. C., Murray-Ramcharan, M., & Donaldson, B. (2020) · Journal of Medical Internet Research · doi:10.2196/20548 · Cited by 40
Diverse roles of long non‐coding RNAs in viral diseases
GINN, L. H., Montagna, M. L., Wu, Q., & Shi, L. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2198 · Cited by 40
Roussel, R., Darmon, P., Pichelin, M., Goronflot, T., Abouleka, Y., Bachir, L. A., Allix, I., Ancelle, D., Barraud, S., Bordier, L., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14324 · Cited by 40
The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity
Bolouri, H., Speake, C., Skibinski, D. A. G., Long, S. A., Hocking, A. M., Campbell, D., Hamerman, J. A., Malhotra, U., & Buckner, J. H. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143648 · Cited by 40
Mondal, S., Dasgupta, R., Lodh, M., Gorai, R., Choudhury, B., Hazra, A. K., & Ganguly, A. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.03.022 · Cited by 40
COVID-19 in pregnancy: What we know from the first year of the pandemic
Arthurs, A. L., Jankovic‐Karasoulos, T., & Roberts, C. T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166248 · Cited by 41
Multivalent nanomedicines to treat COVID-19: A slow train coming
Tabish, T. A., & Hamblin, M. R. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100962 · Cited by 39
Conway, J., Gould, A., Westley, R., Raju, S. A., Oklopcic, A., Broadbent, A., Abdelhafiz, A., & Sinclair, A. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108460 · Cited by 39
The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID ‐19
Xu, Z., Wang, Z., Wang, S., Ye, Y., Luo, D., Wan, L., Yu, A., Sun, L., Tesfaye, S. H., Meng, Q., et al. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13084 · Cited by 39
Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections
Sun, B., Huang, S., & Zhou, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.592439 · Cited by 39
Association between 25-OH Vitamin D Deficiency and COVID-19 Severity in Pregnant Women
Vásquez-Procopio, J., Torres‐Torres, J., Borboa-Olivares, H. J., y Sosa, S. E., Martinez-Portilla, R. J., Solis‐Paredes, J. M., Tolentino‐Dolores, M., Helguera‐Repetto, A. C., Marrufo-Gallegos, K. C., Missirlis, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315188 · Cited by 38
Singh, A. K., Singh, R., Saboo, B., & Misra, A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.12.026 · Cited by 38
A Glimpse into Milestones of Insulin Resistance and an Updated Review of Its Management
Aedh, A. I., Alshahrani, M. S., Huneif, M. A., Pryme, I. F., & Oruch, R. (2023) · Nutrients · doi:10.3390/nu15040921 · Cited by 38
The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients
Du, H., Wang, D. W., & Chen, C. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15674 · Cited by 36
Sriram, K., Loomba, R. S., & Insel, P. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009875117 · Cited by 36
Kroemer, M., Spehner, L., Vettoretti, L., Bouard, A., Eberst, G., Pili Floury, S., Capellier, G., Lepiller, Q., Orillard, E., Mansi, L., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2020.08.036 · Cited by 35
DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?
Krejner‐Bienias, A., Grzela, K., & Grzela, T. (2021) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-020-00602-5 · Cited by 35
The phospholipase A2 family’s role in metabolic diseases: Focus on skeletal muscle
Cervera, I. P., Gabriel, B. M., Aldiss, P., & Morton, N. M. (2021) · Physiological Reports · doi:10.14814/phy2.14662 · Cited by 35
Risk of infection and hospitalization by Covid-19 in Mexico: a case-control studyPreprint
Berumen-Campos, J., Schmulson, M. J., Alegre-Díaz, J., Guerrero, G., Oláiz, G., Wong‐Chew, R. M., Larriva-Sahd, J. A., Cantú-Brito, C. G., Ochoa-Guzmán, A., Garcilazo‐Ávila, A., et al. (2020) · medRxiv · doi:10.1101/2020.05.24.20104414 · Cited by 35
Alag, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239694 · Cited by 34
Diabetes in COVID‐19 pandemic‐prevalence, patient characteristics and adverse outcomes
Abdelhafiz, A. H., Emmerton, D., & Sinclair, A. J. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14112 · Cited by 34
Polycystic ovary syndrome and risks for COVID-19 infection: A comprehensive review
de Medeiros, S. F., Yamamoto, M. M. W., de Medeiros, M. A. S., Yamamoto, A. K. L. W., & Barbosa, B. B. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09715-y · Cited by 34
Gujral, U. P., Johnson, L. C. M., Nielsen, J., Vellanki, P., HAW, J. S., Davis, G. M., Weber, M. B., & Pasquel, F. J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001520 · Cited by 33
Ramos-Rincón, J. M., Perez-Belmonte, L. M., Carrasco-Sánchez, F. J., Jansen‐Chaparro, S., de-Sousa-Baena, M., Fonseca, J. B., Pérez-Aguilar, M., Arévalo-Cañas, C., Cebrián, M. B., Méndez‐Bailón, M., et al. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab124 · Cited by 33
Cavallaro, M., Moiz, H., Keeling, M. J., & McCarthy, N. D. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009121 · Cited by 32
Glucagon‐like peptide‐1 receptor agonists in the era of COVID ‐19: Friend or foe?
Belančić, A., Kresović, A., & Dijan, M. (2021) · Clinical Obesity · doi:10.1111/cob.12439 · Cited by 32
Rehman, S. U., & Tabish, M. (2020) · Clinical Science · doi:10.1042/cs20200419 · Cited by 31
Ahmed, S., Barbera, L. C., Bartlett, S. J., Bebb, D. G., Brundage, M., Bryan, S., Cheung, W. Y., Coburn, N. G., Crump, T., Cuthbertson, L., et al. (2020) · Current Oncology · doi:10.3747/co.27.6399 · Cited by 31
Chakravarti, H. N., & Nag, A. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01330-5 · Cited by 31
Regis, B. C., Fernandes, A. S. T., Pol-Fachin, L., & Campion, A. (2020) · Brazilian Journal of Health Review · doi:10.34119/bjhrv3n5-029 · Cited by 30
COVID-19 and obesity: the meeting of two pandemics
Brandão, S. C. S., Godoi, E. T. A. M., Cordeiro, L. H. D. O., Bezerra, C., Ramos, J. D. O. X., de Arruda, G. F. A., & Lins, E. M. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000318 · Cited by 30
Admin, A., Batchu, S. N., Kaur, H., Yerra, V. G., Advani, S. L., Kabir, G., Liu, Y., Klein, T., & Advani, A. (2020) · Diabetes · doi:10.2337/db20-0765 · Cited by 30
Boye, K. S., Erdemir, E. T., Zimmerman, N. D., Reddy, A., Benneyworth, B. D., Dabora, M. C., Hankosky, E. R., Bethel, M. A., Clark, C. N., Lensing, C. J., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01110-1 · Cited by 31
Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
Hu, X., Wang, X., & Xue, X. (2022) · Molecules · doi:10.3390/molecules27144498 · Cited by 30
Yin, Y., Rohli, K. E., Shen, P., Lu, H., Liu, Y., Dou, Q., Zhang, L., Kong, X., Yang, S., & Jia, P. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.08.014 · Cited by 30
Sato, T., Shimizu, T., Fujita, H., Imai, Y., Drucker, D. J., Seino, Y., & Yamada, Y. (2020) · Endocrinology · doi:10.1210/endocr/bqaa201 · Cited by 29
Self-citationInfante, M., Ricordi, C., & Fabbri, A. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13053 · Cited by 29
Dedov, I. I., Mokrysheva, N. G., Shestakova, M. V., Nikonova, T. V., Mayorov, A. Y., Galstyan, G. R., Shamhalova, M. S., Барышева, В. О., As, A., Antsiferov, M. B., et al. (2022) · Diabetes Mellitus · doi:10.14341/dm12873 · Cited by 29
Filho, B. F. D. L., Bessa, N. P. O. S., Fernandes, A. C. T., Patrício, Í. F. D. S., Alves, N. D. O., & Cavalcanti, F. A. D. C. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01580-y · Cited by 27
Molecular-Level Anatomy of SARS-CoV-2 for the Battle against the COVID-19 Pandemic
Komiyama, M. (2021) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20210030 · Cited by 27
Differential Impact of COVID-19 Risk Factors on Ethnicities in the United States
Athavale, P., Kumar, V., Clark, J., Mondal, S., & Sur, S. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.743003 · Cited by 28
Whole-body metabolic modelling predicts isoleucine dependency of SARS-CoV-2 replication
Thiele, I., & Fleming, R. M. T. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.019 · Cited by 27
The COVID-19 Pandemic during the Time of the Diabetes Pandemic: Likely Fraternal Twins?
Cole, S. A., Laviada‐Molina, H., Serres-Perales, J. M., Rodríguez-Ayala, E., & Bastarrachea, R. A. (2020) · Pathogens · doi:10.3390/pathogens9050389 · Cited by 26
Šmelcerović, A., Kocic, G. M., Gajić, M., Tomović, K., Djordjevic, V., Stankovic‐Djordjevic, D., & Anderluh, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01185 · Cited by 26
Metabolic Perturbations and Severe COVID-19 Disease: Implication of Molecular Pathways
Nigro, E., Perrotta, F., Polito, R., D’Agnano, V., Scialò, F., Bianco, A., & Daniele, A. (2020) · International Journal of Endocrinology · doi:10.1155/2020/8896536 · Cited by 26
Martynowicz, H., Jodkowska, A., Poręba, R., Mazur, G. J., & Wieckiewicz, M. A. (2021) · Dental and Medical Problems · doi:10.17219/dmp/131795 · Cited by 25
Rajendran, R., Chathambath, A., Al-Sehemi, A. G., Pannipara, M., Unnikrishnan, M. K., Aleya, L., Raghavan, R. P., & Mathew, B. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-19148-4 · Cited by 25
COVID-19 and diabetes—Two giants colliding: From pathophysiology to management
Pelle, M. C., Zaffina, I., Provenzano, M., Moirano, G., & Arturi, F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.974540 · Cited by 26
Resolviendo una de las piezas del puzle: COVID-19 y diabetes tipo 2
Pérez‐Martínez, P., Carrasco-Sánchez, F. J., Carretero‐Gómez, J., & Gómez‐Huelgas, R. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.05.003 · Cited by 24
Prevalence and impact of diabetes in patients with COVID-19 in China
Du, M., Lin, Y., Yan, W., Tao, L., Liu, M., & Liu, J. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i10.468 · Cited by 24
Myers, A. K., Kim, T. S., Zhu, X., Liu, Y., Qiu, M., & Pekmezaris, R. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13158 · Cited by 24
Laviada‐Molina, H., Leal‐Berumen, I., Rodríguez-Ayala, E., & Bastarrachea, R. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00514 · Cited by 24
Márquez‐Salinas, A., Fermín‐Martínez, C. A., Antonio‐Villa, N. E., Vargas‐Vázquez, A., Guerra, E. C., Campos-Muñoz, A., Zavala‐Romero, L., Mehta, R., Bahena-López, J. P., Ortíz‐Brizuela, E., et al. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab078 · Cited by 24
Wallia, A., Prince, G., Touma, E., El Muayed, M., & Seley, J. J. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01366-0 · Cited by 23
Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection
Bielka, W., Przezak, A., & Pawlik, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147605 · Cited by 23
Who wants to reopen the economy during the COVID-19 pandemic? The daring and uncaring
Howard, M. C. (2020) · Personality and Individual Differences · doi:10.1016/j.paid.2020.110335 · Cited by 23
Pinedo-Torres, I. A., Flores-Fernández, M., Yovera-Aldana, M., Gutiérrez‐Ortiz, C., Zegarra-Lizana, P. A., Intimayta‐Escalante, C., Morán‐Mariños, C., Alva‐Díaz, C., & Pacheco‐Barrios, K. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420962495 · Cited by 22
Stress Hyperglycemia Ratio as a Prognostic Marker in Diabetic Patients Hospitalized with COVID-19
Aon, M. H., Alsaeedi, A., Alzafiri, A., Al-Shammari, A., Taha, S. N., Al-Shammari, O., Tawakul, M., Alshammari, J., Alherz, N., Alenezi, M., et al. (2022) · Infectious Disease Reports · doi:10.3390/idr14050073 · Cited by 22
In Vitro Data of Current Therapies for SARS-CoV-2
Anastasiou, I. A., Eleftheriadou, I., Tentolouris, A., Tsilingiris, D., & Tentolouris, N. (2020) · Current Medicinal Chemistry · doi:10.2174/1875533xmta2jntcby · Cited by 22
COVID-19: Are Non-Communicable Diseases Risk Factors for Its Severity?
Bello, B., & Useh, U. (2021) · American Journal of Health Promotion · doi:10.1177/0890117121990518 · Cited by 23
Guardado‐Mendoza, R., Garcia-Magaña, M. A., Martínez-Navarro, L. J., Macías-Cervantes, H. E., Aguilar-Guerrero, R., Suárez-Pérez, E. L., & Aguilar-García, A. (2022) · Scientific Reports · doi:10.1038/s41598-021-04511-1 · Cited by 22
ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?
Monda, V. M., Porcellati, F., Strollo, F., & Gentile, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00898-8 · Cited by 21
Bibliometric and visual analysis of cardiovascular diseases and COVID-19 research
Wei, N., Xu, Y., Wang, H., Jia, Q., Shou, X., Zhang, X., Zhang, N., Li, Y., Zhai, H., & Hu, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1022810 · Cited by 21
Abumayyaleh, M., Nuñez-Gil, I. J., Viana-Llamas, M. C., Raposeiras‐Roubín, S., Romero, R., Alfonso‐Rodríguez, E., Uribarri, A., Feltes, G. I., Becerra‐Muñoz, V. M., Santoro, F., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1167087 · Cited by 21
Shukla, A. K., Awasthi, K., Usman, K., & Banerjee, M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i4.606 · Cited by 21
Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
Srivastava, S. P., Srivastava, R., Chand, S., & Goodwin, J. E. (2021) · Pharmaceuticals · doi:10.3390/ph14080751 · Cited by 21
Insight on Infections in Diabetic Setting
Pari, B., Gallucci, M., Ghigo, A., & Brizzi, M. F. (2023) · Biomedicines · doi:10.3390/biomedicines11030971 · Cited by 21
Bai, Y., Lian, P., Li, J., Zhang, Z., & Jian, Q. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104645 · Cited by 21
Research Progress on Dipeptidyl Peptidase Family: Structure, Function and Xenobiotic Metabolism
Qian, X., Zhang, J., Li, X., Song, P., & Zou, L. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210915103431 · Cited by 20
А.А., Д., Faizova, R., О.А., Ю., Belyaeva, T., Терехова, Т. И., Khismetova, A., Sarría‐Santamera, A., Bokov, D. O., Ivankov, A., & Glushkova, N. (2020) · Heliyon · doi:10.1016/j.heliyon.2021.e06561 · Cited by 20
Long, H., Li, J., Li, R., Zhang, H., Ge, H., Zeng, H., Chen, X., Lu, Q., Jiang, W., Zeng, H., et al. (2022) · Epidemiology and Infection · doi:10.1017/s095026882200022x · Cited by 20
Meng, M., Zhao, Q., Kumar, R., Bai, C., Deng, Y., & Wan, B. (2020) · Aging · doi:10.18632/aging.103991 · Cited by 19
Coronavirus Disease 2019 and Diabetes: The Epidemic and the Korean Diabetes Association Perspective
Noh, J. H., Chang, H., Jeong, I., & Yoon, K. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0138 · Cited by 19
SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management
Mihăescu, G., Chifiriuc, M. C., Iliescu, C., Vrâncianu, C. O., Diţu, L.-M., Marutescu, L. G., Grigore, R., Bertesteanu, S. V., Constantin, M., & Pîrcălăbioru, G. G. (2020) · Microorganisms · doi:10.3390/microorganisms8101468 · Cited by 19
Rojas, A., Lindner, C., González, I., & Morales, M. A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.590 · Cited by 20
Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
Infante, M., Padilla, N., Alejandro, R., Caprio, M., Della‐Morte, D., Fabbri, A., & Ricordi, C. (2022) · Medicina · doi:10.3390/medicina58050571 · Cited by 19
Metabolic syndrome and COVID-19
Matias, J. N., Campanari, G. S. D. S., de Souza, G. A., Lima, V. M., Tofano, R. J., Detregiachi, C. R. P., & Barbalho, S. M. (2020) · AIMS bioengineering · doi:10.3934/bioeng.2020021 · Cited by 18
COVID-19: A Challenge to Physiology of Aging
Golubev, A. G. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.584248 · Cited by 18
Reges, O., Test, T., Hoshen, M., Cicurel, A., Saliba, W., Greenland, P., Dicker, D., & Lavie, G. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003052 · Cited by 18
New-onset diabetes in COVID-19: The molecular pathogenesis
Wihandani, D. M., Purwanta, M. L. A., Mulyani, W. R. W., Putra, I. W. A. S., & Supadmanaba, I. G. P. (2023) · Biomedicine · doi:10.37796/2211-8039.1389 · Cited by 18
Diabetes and susceptibility to infections: Implication for COVID‐19
van Niekerk, G., van der Merwe, M., & Engelbrecht, A. (2021) · Immunology · doi:10.1111/imm.13383 · Cited by 18
Increased morbidity of obese mice infected with mouse-adapted SARS-CoV-2
Zhang, Y., Zhang, Z., Zhang, H., Li, X., Li, J., Zhang, Q., Liu, J., Li, Q., Deng, C., Shi, Z., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00305-x · Cited by 18
Alberti, A., Schuelter‐Trevisol, F., Iser, B. P. M., Traebert, E., Freiberger, V., Ventura, L., Rezin, G. T., da Silva, B. B., Dallacosta, F. M., Grigollo, L. R., et al. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i20.5358 · Cited by 17
Pathophysiology of SARS-CoV-2 in Lung of Diabetic Patients
de Oliveira, T. L., de Melo, I. S., Cardoso-Sousa, L., Santos, I. A., Zoghbi, M. B. E., Shimoura, C. G., Georjutti, R. P., de Castro, O. W., Goulart, L. R., Jardim, A. C. G., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.587013 · Cited by 17
Jiang, L., Lu, L., Xue, C., Sun, H., Ren, K., Zhang, L., Zhu, H., Zhang, B., Wang, X., Qiao, X., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00926-4 · Cited by 16
Ferrannini, G., Lund, L. H., Benson, L., Rizzo, M., Almahmeed, W. A., Rosano, G. M. C., Savarese, G., & Cosentino, F. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac044 · Cited by 16
Demidova, T. Y., Volkova, E., & Gritskevich, Е. Y. (2020) · Obesity and metabolism · doi:10.14341/omet12663 · Cited by 16
Severity of COVID-19 and Treatment Strategy for Patient With Diabetes
Jin, S., & Hu, W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.602735 · Cited by 16
Theory and Practice of Aging during the COVID-19 Pandemic
Golubev, A. G., & Sidorenko, A. (2020) · Advances in Gerontology · doi:10.1134/s2079057020040062 · Cited by 15
Nexus of COVID-19 and diabetes pandemics: Global public health lessons
Bergman, M., Jagannathan, R., & Narayan, K. M. V. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108215 · Cited by 15
Iqbal, A., Greig, M., Arshad, M. F., Julian, T. H., Tan, S. E., & Elliott, J. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108955 · Cited by 15
Metadata
- Authors
- Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J
- ORCID
- Drucker, Daniel J
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-04-15
- Volume
- 41
- Issue
- 3
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7184382
- OpenAlex
- W3015989800
- Cited by
- 399
- References
- 132
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 13 · 2023: 37 · 2022: 72 · 2021: 100 · 2020: 162
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Fonden (NNF19SA0035502)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- type 2 diabetes, COVID-19 pandemic, SARS-CoV-2, ACE2, dipeptidyl peptidase IV, DPP-4 inhibitors, glucose-lowering agents, immunomodulation, glucose homeostasis, inflammation
- MeSH terms
- Betacoronavirus, Receptors, Coronavirus, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, Animals, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Insulin, Peptidyl-Dipeptidase A, Lung, Obesity, Pneumonia, Viral, Receptors, Virus, Risk Factors, Serine Endopeptidases, Coronavirus Infections, Dipeptidyl Peptidase 4, Gastrointestinal Tract, Dipeptidyl-Peptidase IV Inhibitors, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.